Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a strong pipeline of monoclonal antibodies focused on infectious disease and is now deploying CellSpot in the field of oncology. Trellis has discovered its first antibodies against cancer antigens in the blood of healthy donors forming the foundation of its innovative cancer program. Trellis also applies CellSpot’s rare antibody capability to identify anti-drug antibodies (ADAs) for pharmaceutical partners.

Our new address effective January 5, 2013:

1505-B O’Brien Drive
Menlo Park, CA  94025